You are here

Generic Bupropion HCl Sustained Release Tablets Launched

CORONA, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading specialty pharmaceutical company, announced today that, under a supply agreement with GlaxoSmithKline (GSK), the Company has initiated shipments of bupropion hydrochloride sustained-release tablets, in the 100mg strength. The product is the generic version of GlaxoSmithKline's Wellbutrin SR(R) which is indicated for the treatment of depression. For the 12-months ending November 2003, Wellbutrin SR(R) 100mg had sales of approximately $300 million, according to IMS data.

Under a previously announced settlement with GSK, Watson received rights in the United States (US) market to distribute 100mg and 150mg bupropion hydrochloride sustained-release tablets, manufactured by a GSK subsidiary, on a per strength basis, once a third party launches a fully substitutable generic equivalent of the relevant strength of these products in the US market. Watson currently has rights to ship only the 100mg strength of bupropion hydrochloride sustained-release tablets. GSK will receive a share of the profits from Watson's sales of generic bupropion hydrochloride sustained release tablets in the US market. Terms of the agreement were not disclosed.

Source: Watson Pharmaceuticals, Inc.

More Headlines

Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes